IVA (Inventiva) ROCE %: -211.65% (As of Dec. 2025)


IVA Inventiva SA IVA
40 GF Score
Price $3.48
GF Value $0.27
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Inventiva ROCE %?

Inventiva IVA -6.36% 40 ROCE % is -211.65% as of Dec. 2025. GuruFocus rates IVA with a GF Score™ of 40/100 and a GF Value™ of $0.27 (Significantly Overvalued). The stock has 7 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Inventiva's annualized ROCE % for the quarter that ended in Dec. 2025 was -211.65%.

Inventiva  (NAS:IVA) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Inventiva ROCE % Related Terms

Inventiva ROCE % Historical Data

* Premium members only.

The historical data trend for Inventiva's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Inventiva ROCE % Chart

Inventiva Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -42.05 -56.10 -204.64 -1,862.21 -375.89

Inventiva Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -393.08 -1,598.10 0.00 -560.73 -211.65
IVA
40GF Score
Inventiva SA IVA
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Inventiva ROCE % Calculation

Inventiva's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-375.35/( ( (124.573 - 126.42) + (292.167 - 90.607) )/ 2 )
=-375.35/( (-1.847+201.56)/ 2 )
=-375.35/99.8565
=-375.89 %

Inventiva's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=-360.37/( ( (206.407 - 67.426) + (292.167 - 90.607) )/ 2 )
=-360.37/( ( 138.981 + 201.56 )/ 2 )
=-360.37/170.2705
=-211.65 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -211.65% mean?
Inventiva (IVA) has a ROCE % of -211.65% as of Dec. 2025.
Is Inventiva's ROCE % too high?
Inventiva's current ROCE % is -211.65%. Overall, Inventiva has a GF Score™ of 40/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Inventiva's ROCE % compare to VRTX and REGN?
Inventiva's ROCE % of -211.65% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Inventiva's current ROCE % is -211.65%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inventiva stock overvalued right now?
Based on GuruFocus' analysis, Inventiva (IVA) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.27, compared to a current price of $3.48 — trading 1188.9% above its estimated fair value. The current ROCE % is -211.65%. Inventiva's overall GF Score™ is 40/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Inventiva (IVA), the current ROCE % is -211.65% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Inventiva (IVA) Overvalued in 2026?

Based on GuruFocus' analysis, Inventiva stock appears to be overvalued. The current stock price of $3.48 is trading 1188.9% above its estimated GF Value™ of $0.27. GuruFocus considers Inventiva to be Significantly Overvalued.

Key valuation signals for IVA:

  • ROCE %: -211.65%
  • GF Value™: $0.27 vs. price of $3.48 (1188.9% above fair value)
  • GF Score™: 40/100 with 7 warning signs

No single metric tells the full story. See the IVA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Inventiva Business Description

Address 50 rue de Dijon, Daix, FRA, 21121
Inventiva SA is a France-based clinical-stage biopharmaceutical company focused on the development of oral small-molecule therapies for the treatment of MASH. The wholly-owned research and development facility and a team with expertise and experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging the expertise, the company is also advancing lanifibranor for the treatment of MASH and has a pipeline of earlier-stage therapeutic programs in oncology. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France.
40GF Score

Get the complete analysis for IVA

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.48
Price
$0.27
GF Value